The skincare and beauty market in India is witnessing strong growth, driven by rising awareness, higher disposable incomes, and increasing digital penetration. The Indian skincare market, valued at $2 billion in 2022, is projected to grow at a CAGR of 9.5% over the next five years. However, access to quality dermatological care remains limited, with only one dermatologist per 120,000 Indians, predominantly concentrated in tier-1 cities. This accessibility gap, combined with a growing focus on personalized, evidence-based skincare, creates a ripe opportunity for tech-driven solutions like CureSkin.

CureSkin addresses this challenge through its AI-powered platform, which analyzes user-uploaded photos to diagnose skin conditions and recommend personalized treatment plans. The platform’s AI engine, trained on 25 million+ images, provides highly accurate assessments, while its 110+ private-label SKUs offer tailored solutions. By integrating dermatologist consultations with its automated recommendation engine, CureSkin reduces consultation time while improving accuracy and customer trust. The platform’s expansion into hair and body care further enhances its market potential.

Founded by Guna Kakulapati, Ramakrishna R and Dr. Charu Sharma, CureSkin’s leadership brings strong domain expertise in AI, healthcare, and consumer technology. Their focus on data-driven skincare solutions and the shift toward private-label products allows for greater control over product quality and margins.

We invested in CureSkin as it aligns with our thesis of backing AI-powered, scalable platforms addressing large, underserved markets. With its tech-driven approach, expanding product lines, and growing consumer trust, CureSkin is well-positioned to capitalize on the rising demand for accessible and effective dermatological solutions.